Tharimmune, Inc. — Director's Dealing 2022

Jan 12, 2022

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Hillstream BioPharma Inc. (HILS)
CIK: 0001861657
Period of Report: 2022-01-11

Reporting Person: MILBY RANDY (Director, Chief Executive Officer)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Options (right to purchase)	$13.20	2023-06-20	Common stock (18939)		Direct
Options (right to purchase)	$13.20	2023-09-20	Common stock (10984)		Direct
Options (right to purchase)	$0.079	2024-07-31	Common Stock (37878)		Direct
Options (right to purchase)	$0.079	2024-08-30	Common stock (189393)		Direct
Options (right to purchase)	$2.64	2024-09-17	Common stock (1893)		Direct
Options (right to purchase)	$2.64	2024-09-19	Common stock (1893)		Direct
Options (right to purchase)	$2.64	2024-11-05	Common stock (946)		Direct
Options (right to purchase)	$2.64	2024-12-13	Common stock (7575)		Direct
Options (right to purchase)	$2.64	2024-12-31	Common stock (37878)		Direct
Options (right to purchase)	$0.314	2030-01-31	Common stock (7575)		Direct
Options (right to purchase)	$0.314	2030-02-28	Common stock (7575)		Direct
Options (right to purchase)	$0.314	2030-03-31	Common Stock (7575)		Direct
Options (right to purchase)	$0.314	2030-04-30	Common stock (7575)		Direct
Options (right to purchase)	$0.314	2030-05-31	Common stock (7575)		Direct
Options (right to purchase)	$0.314	2030-06-30	Common stock (7575)		Direct
Options (right to purchase)	$0.314	2030-07-31	Common stock (7575)		Direct
Options (right to purchase)	$0.314	2030-08-31	Common stock (7575)		Direct
Options (right to purchase)	$0.314	2030-09-30	Common stock (7575)		Direct
Options (right to purchase)	$3.817	2030-10-31	Common stock (7575)		Direct
Options (right to purchase)	$3.817	2030-11-12	Common stock (7575)		Direct
Options (right to purchase)	$3.817	2030-11-12	Common stock (37878)		Direct
Options (right to purchase)	$3.817	2030-11-30	Common stock (7575)		Direct
Options (right to purchase)	$3.817	2030-12-31	Common stock (7575)		Direct
Options (right to purchase)	$7.822	2031-01-31	Common stock (18939)		Direct
Options (right to purchase)	$7.822	2031-02-01	Common stock (45454)		Direct
Options (right to purchase)	$7.822	2031-02-28	Common stock (18939)		Direct
Options (right to purchase)	$7.822	2026-03-31	Common stock (18939)		Direct
Options (right to purchase)	$7.822	2031-04-02	Common stock (37878)		Direct
Options (right to purchase)	$7.822	2031-04-30	Common stock (18939)		Direct
Options (right to purchase)	$7.822	2031-05-31	Common stock (18939)		Direct

Footnotes

F1: The Registrant issued the Reporting Person the options on June 20, 2018. The options vest as follows: (i) 3,787 options vested on the date of grant and became exercisable on June 20, 2019 and (ii) the balance of the options shall vest and become exercisable in 48 equal monthly installments with the first installment vesting on July 20, 2019.

F2: The Registrant issued the Reporting Person the options on September 20, 2018. The options vest as follows: (i) 3,787 options vested on the date of grant and became exercisable on September 20, 2019 and (ii) the balance of the options shall vest and become exercisable in 48 equal monthly installments with the first installment vesting on October 20, 2019.

F3: The Registrant issued the Reporting Person the options on July 31, 2019. The options vest as follows: (i) 9,469 options vested and became exercisable on July 31, 2020 and (ii) the balance of the options shall vest and become exercisable in 48 equal monthly installments with the first installment vesting on August 31, 2020.

F4: The Registrant issued the Reporting Person the options on August 30, 2019. The options vested on the date of grant and become exercisable on the completion of the Registrant's initial public offering or a public listing via a reverse merger with a public company.

F5: The Registrant issued the Reporting Person the options on September 17, 2019. The options vest as follows: (i) 473 options vested and became exercisable on September 17, 2020 and (ii) the balance of the options shall vest and become exercisable in 48 equal monthly installments with the first installment vesting on October 31, 2020.

F6: The Registrant issued the Reporting Person the options on September 19, 2019. The options vest as follows: (i) 473 options vested and became exercisable on September 19, 2020 and (ii) the balance of the options shall vest and become exercisable in 48 equal monthly installments with the first installment vesting on October 31, 2020.

F7: The Registrant issued the Reporting Person the options on November 5, 2019. The options vest as follows: (i) 236 options vested and became exercisable on November 5, 2020 and (ii) the balance of the options shall vest and become exercisable in 48 equal monthly installments with the first installment vesting on December 31, 2020.

F8: The Registrant issued the Reporting Person the options on December 13, 2019. The options vest as follows: (i) 3,787 options vested on the date of grant and became exercisable on December 13, 2020 and (ii) the balance of the options shall vest and become exercisable in 48 equal monthly installments with the first installment vesting on January 31, 2020.

F9: The Registrant issued the Reporting Person the options on December 31, 2019. The options vest as follows: (i) 9,469 options vested and became exercisable on December 31, 2020 and (ii) the balance of the options shall vest and become exercisable in 48 equal monthly installments with the first installment vesting on January 31, 2020.